Acadia Pharmaceuticals

Automation Project Engineer (m/w/d)

Kiel, Schleswig-Holstein, Germany

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, Automation, EngineeringIndustries

Requirements

Candidates should possess an completed degree in Automation Technology, with a minimum of 5 years of professional experience in Process Control Technology or Automation Technology, preferably with expertise in the pharmaceutical industry and knowledge of GMP-relevant guidelines.

Responsibilities

The Automation Project Engineer will lead projects related to automation and networking, from concept to acceptance according to Ferring standards, create specifications and review requirement documents, collaborate closely with Engineering, IT, Quality Assurance, and Production, oversee sub-suppliers during commissioning and troubleshooting, design automation systems and networks, contribute to the development of existing automation systems and their integration into the Ferring network, analyze and maintain existing software on SPS and SCADA, participate practically and conceptually in the design of new production lines in the area of automation, document changes and plant expansions, conduct repairs and troubleshooting, and implement development and design changes to improve quality and reduce costs.

Skills

SPS
SCADA
Automation
Process Control
GMP
Networking
Troubleshooting
Design
Development
Integration
Requirements Analysis
Documentation

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Key Metrics

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI